-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

Benzinga·09/22/2026 10:31:01
HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $67 price target.